Copyright © 1988 by the European Society of Cardiology.
© 1988 The European Society of Cardiology
A comparison of digoxin, diltiazem and their combination in the treatment of atrial fibrillation
Department of Pharmacology and Clinical Pharmacology, Ninewells Hospital and Medical School Dundee DD19SY, U.K.
Received 6 April 1987; revised 10 August 1987; .
Abstract
Fourteen patients (four females) with chronic atrial fibrillation were entered into a randomized, double-blind crossover study to compare the effects of treatment with diltiazem alone, digoxin alone, and a combination of diltiazem plus digoxin. The dose of digoxin was adjusted so as to achieve serum concentrations within the range 1.3–2.6 nmoll–1 between six and eight hours after dosing. Four patients were withdrawn from the study; three patients experienced side effects while taking diltiazem and one reverted to sinus rhythm while taking digoxin. Among the remaining 10 patients, mean heart rates were significantly lower during treatment with the combination of digoxin and diltiazem than with digoxin alone both at rest, after exercise and during ambulatory ECG monitoring. Post-exercise heart rates were reduced by 15% with combination therapy when compared with digoxin alone (151.9 vs. 128.1 bpm), but there was no evidence that this reduction in ventricular rate was associated with improved exercise tolerance. The results suggest that further reduction of the rapid ventricular rates seen in digitalized patients with AF by the use of diltiazem does not appear to be of benefit in the majority of patients.
Key Words: Digoxin • diltiazem • atrial fibrillation
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Nikolaidou and K. S Channer Rate control in permanent atrial fibrillation BMJ, November 24, 2007; 335(7629): 1057 - 1058. [Full Text] [PDF]
|
|
|
|
 |
|
 A J Camm, I Savelieva, G Y H Lip, and on behalf of the Guideline Development Group for t Rate control in the medical management of atrial fibrillation Heart, January 1, 2007; 93(1): 35 - 38. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Snow, K. B. Weiss, M. LeFevre, R. McNamara, E. Bass, L. A. Green, K. Michl, D. K. Owens, J. Susman, D. I. Allen, et al. Management of Newly Detected Atrial Fibrillation: A Clinical Practice Guideline from the American Academy of Family Physicians and the American College of Physicians Ann Intern Med, December 16, 2003; 139(12): 1009 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. McNamara, L. J. Tamariz, J. B. Segal, and E. B. Bass Management of Atrial Fibrillation: Review of the Evidence for the Role of Pharmacologic Therapy, Electrical Cardioversion, and Echocardiography Ann Intern Med, December 16, 2003; 139(12): 1018 - 1033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Wattanasuwan, I. A. Khan, N. J. Mehta, P. Arora, N. Singh, B. C. Vasavada, and T. J. Sacchi Acute Ventricular Rate Control in Atrial Fibrillation : IV Combination of Diltiazem and Digoxin vs IV Diltiazem Alone Chest, February 1, 2001; 119(2): 502 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Levy, S Walker, M Mason, P Spurrell, S Rex, S Brant, and V Paul Importance of rate control or rate regulation for improving exercise capacity and quality of life in patients with permanent atrial fibrillation and normal left ventricular function: a randomised controlled study Heart, February 1, 2001; 85(2): 171 - 178. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. Dorian, W. Jung, D. Newman, M. Paquette, K. Wood, G. M. Ayers, J. Camm, M. Akhtar, and B. Luderitz The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1303 - 1309. [Abstract] [Full Text] [PDF]
|
|